# Comparison Of Efficacy Of Tazarotene 0.045% Vs Halobetasol Propionate 0.01% Lotion For Treatment of Scalp Psoriasis

> **NCT06015152** · NA · COMPLETED · sponsor: **Jinnah Postgraduate Medical Centre** · enrollment: 90 (actual)

## Conditions studied

- Scalp Psoriasis

## Interventions

- **DRUG:** Tazarotene 0.045% Topical Application Lotion [ARAZLO]

## Key facts

- **NCT ID:** NCT06015152
- **Lead sponsor:** Jinnah Postgraduate Medical Centre
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-01
- **Primary completion:** 2022-12-01
- **Final completion:** 2023-02-01
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2023-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06015152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06015152, "Comparison Of Efficacy Of Tazarotene 0.045% Vs Halobetasol Propionate 0.01% Lotion For Treatment of Scalp Psoriasis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06015152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*